Switching antidepressant therapy is a recommended strategy for depressed patients who neither respond to nor tolerate an initial pharmacotherapy course. This paper reviews the efficacy and tolerability of switching to vortioxetine. All three published studies of patients with major depressive disorder (MDD) switched from SSRI/SNRI therapy to vortioxetine due to lack of efficacy or tolerability were selected. Vortioxetine was evaluated versus agomelatine directly (REVIVE) and versus sertraline, venlafaxine, bupropion, and citalopram in an indirect treatment comparison (ITC) from switch studies retrieved in a literature review. Vortioxetine's impact on SSRI-induced treatmentemergent sexual dysfunction (TESD) was assessed directly versus escitalopram (NCT01364649) in stable patients with MDD. Vortioxetine's tolerability in the switch population was compared to the overall MDD population. Vortioxetine showed significant benefits over agomelatine on efficacy, functioning, and quality-of-life outcomes, with fewer withdrawals due to adverse events (AEs) (REVIVE). Vortioxetine had numerically higher remission rates versus all therapies included (ITC). Withdrawal rates due to AEs were significantly lower for vortioxetine versus sertraline, venlafaxine, and bupropion, and numerically lower versus citalopram. Switching to vortioxetine was statistically superior to escitalopram in improving TESD (NCT01364649). Tolerability was similar in the switch and overall MDD populations. These findings suggest that vortioxetine is an effective switch therapy for patients with MDD whose response to SSRI/SNRI therapy is inadequate. Vortioxetine was well tolerated and, for patients with a history of TESD, showed significant advantages versus escitalopram. Vortioxetine appears to be a valid option for patients with MDD who have not been effectively treated with first-line pharmacotherapies.
Introduction
Clinical practice shows that 40-60% of patients with major depressive disorder (MDD) do not respond adequately (e.g., do not achieve Z 50% reduction in depression rating scores) to first-line pharmacotherapies (Bauer et al., 2013; Rush et al., 2006a) and approximately one-third will not remit even after a course of up to 4 sequential treatment steps (Rush et al., 2006a) . Tolerability problems also undermine antidepressant pharmacotherapy; nonadherence and premature discontinuation of medication because of side effects are two of the most common reasons that therapy fails in current practice (Ashton et al., 2005; Masand, 2003) .
On average, half of patients (46-52%) discontinue taking their antidepressant medication as prescribed by the end of the first six months of pharmacotherapy (Sansone and Sansone, 2012) . In one study, in which 60% of patients had completely discontinued treatment, the most common reasons were lack of efficacy (44%), not liking the way the drug made them feel (36%), lack of interest in sex (22%), tiredness (17%), and weight gain (15%) (Ashton et al., 2005) . Furthermore, loss of interest in sex was reported by 47% of all patients prescribed an antidepressant, with inability to have an erection and difficulty reaching orgasm considered to be "extremely difficult to live with" by 25% and 24% of the patients, respectively. Although there are few studies assessing patient self-reported reasons for noncompliance, sexual dysfunction is a commonly reported side effect associated with treatment. A systematic review of the clinical trial data showed that treatment with sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, imipramine, phenelzine, duloxetine, escitalopram, and fluvoxamine was associated with rates of treatment-emergent sexual dysfunction (TESD) that were significantly greater than placebo and that ranged between 25% and 80% (Serretti and Chiesa, 2009 ). Thus, a large proportion of patients with MDD need to switch therapies during the course of treatment.
In contemporary practice, switching antidepressants is one of the more commonly used strategies when the initial course of antidepressant therapy is either ineffective or poorly tolerated. Indeed, in the UK Clinical Practice Research Datalink database analysis, in the group of patients receiving second-line treatment, switching occurred in 39% of cases (Lamy et al., 2015) . A recent multisite study conducted in Spain found that psychiatrists switched 40% of patients who were not well treated with their initial therapy to another antidepressant (Garcia-Toro et al., 2012) . They added a second antidepressant for 24% of patients, while the remainder received augmentation (18%) or mixed strategies (19%). A survey of psychopharmacologists in the United States revealed similar treatment patterns (Goldberg et al., 2015) .
Once the decision has been made to switch antidepressants due to a lack of efficacy or tolerability problems, there is limited evidence to guide the choice of which new agent to prescribe (American Psychiatric Association (APA), 2010; Gaynes et al., 2012 ; National Collaborating Centre for Mental Health (NCCMH), 2010; Santaguida et al., 2012; Tadic et al., 2016) . A recent meta-analysis found few randomized controlled trials that assessed switching after nonresponse and an absence of high-quality data to support switching versus continuing on the same antidepressant (Bschor et al., 2016) . Only a small number of head-to-head studies have assessed the efficacy and tolerability of different antidepressants as switch therapy in individuals who discontinue treatment due to lack of efficacy or intolerable side effects (Kasper and Hajak, 2013; Lenox-Smith and Jiang, 2008; Montgomery et al., 2014; Rush et al., 2006b) . Only one study has undertaken a direct comparison of switch therapies in patients with TESD, one of the most bothersome side effects of antidepressant pharmacotherapy (Ashton et al., 2005) .
Vortioxetine is an approved antidepressant with a multimodal mechanism of action different from that of SSRIs and SNRIs. Vortioxetine has been evaluated as switch therapy using both direct and indirect analyses in patients who experienced inadequate response to SSRI or SNRI therapy and in patients who discontinued therapy because of intolerable TESD. The objective of this review is to summarize the evidence pertaining to using switch therapy in both of these patient populations.
Relative efficacy as switch therapy

Direct treatment comparison
The REVIVE study (Montgomery et al., 2014 ) (NCT01488071) was a prospective, randomized, double-blind, flexible-dose, 12-week study to assess vortioxetine efficacy versus agomelatine in patients with MDD who had experienced an inadequate treatment response after receiving a SSRI or SNRI for a minimum of 6 weeks. Eligible patients were directly switched to vortioxetine (10 or 20 mg/day, n= 252) or agomelatine (25 or 50 mg/day, n= 241). Agomelatine was chosen as the comparator because, like vortioxetine, it has a mechanism of action that is different from SSRIs and SNRIs (Stahl, 2014) . The antidepressant effects of agomelatine are thought to be mediated by its actions as a potent agonist at melatonin MT 1 and MT 2 receptors and as a neutral antagonist at 5-HT 2C receptors (Guardiola-Lemaitre et al., 2014) . This agent is currently not approved for the treatment of MDD in the US, but received that indication from the European Medicines Agency in 2009.
In the primary efficacy analysis, the mean change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 8 (full analysis set, mixed model for repeated measurements) was À16.5 points for vortioxetine and À14.4 points for agomelatine (Figure 1 ). The mean difference between treatments was À2.2 points (95% confidence interval [CI]: À3.5 to À0.8; P = 0.0018), establishing superior efficacy (European Medicines Agency, 2000) with vortioxetine. At Week 12, vortioxetine maintained superiority with a statistically significant mean difference in change from baseline in MADRS total score of À2.0 points (Po0.01) (Figure 1 ).
Efficacy findings were consistent across endpoints (Montgomery et al., 2014) . At Week 8, 61.5% of the patients in the vortioxetine group were MADRS responders (Z50% improvement from baseline in MADRS total score) compared with 47.3% of the agomelatine group (Po0.01), and 40.5% of vortioxetine-treated patients were MADRS remitters (MADRS total score r10) compared with 29.5% of agomelatinetreated patients (Po0.01) (Figure 2) . The difference between study groups was sustained at Week 12: response rates were 69.8% with vortioxetine versus 56.0% with agomelatine (Po0.01), and remission rates were 55.2% with vortioxetine versus 39.4% with agomelatine (Po0.001) (Figure 2 ). These results translated to a statistically significantly higher probability of achieving remission in the vortioxetine group compared with the agomelatine group (risk difference [RD], À11%; Po0.01) (Figure 3) .
Moreover, treatment group differences in the change from baseline at Week 8 in all patient-reported outcomes favored vortioxetine. The mean change from baseline (7 standard error [SE]) on the Sheehan Disability Scale (SDS) total score was À9.28 (75.3) in the vortioxetine group versus À7.06 (70.55) in the agomelatine group (Po0.01) (decreases from baseline scores indicate improvement in functioning). Significant differences favoring vortioxetine were also observed for the SDS family life, work, and social life subscales (Po0.01) (Montgomery et al., 2014) . The mean change from baseline (7SE) in the EuroQol 5 Dimensions overall health state score was 20.6 (71.2) with vortioxetine and 15.6 (71.3) with agomelatine (Po0.01) (higher scores indicate better overall health). The mean change from baseline (7SE) on the Work Limitations Questionnaire global productivity index score was À0.06 (70.00) with vortioxetine versus À0.04 (70.02) with agomelatine (Po0.05) (decreases from baseline scores indicate improvement in productivity). The mean change from baseline (7SE) on the Depression and Family Functioning Scale total score for vortioxetine and agomelatine was À10.8 (70.7) versus À7.9 (70.7) (Po0.01), respectively (Montgomery et al., 2014) (decreases from baseline scores indicate improvement).
Indirect treatment comparison
To further assess the relative efficacy and tolerability of vortioxetine versus other monotherapies, a systematic literature review and generation of the network of evidence for indirect treatment comparisons (ITCs) were selected as the most appropriate analytical methodology for the available data. The general methods used and partial results have been published previously (Brignone et al., 2016) . The ITC included 2 outcomes of interest: rates of remission (defined as either MADRS total score r10 or Hamilton Depression Rating Scale [HAM-D] total score r 7) and rates of withdrawal due to adverse events (AEs).
The network was expanded to include citalopram in addition to vortioxetine, agomelatine, venlafaxine, sertraline, and bupropion, using data from 4 studies (Figure 4) : the REVIVE study (Montgomery et al., 2014) ; a post-hoc analysis of a randomized controlled trial comparing agomelatine with sertraline (Kasper and Hajak, 2013) ; the STAR*D reporting data for sertraline, venlafaxine extended release (XR), and bupropion sustained-release (SR) monotherapy use after treatment failure with citalopram (Rush et al., 2006b) ; and from a randomized, controlled trial comparing venlafaxine XR to citalopram after failure with an SSRI (Lenox-Smith and Jiang, 2008) . Only active-comparator (not placebo) studies evaluating pharmacological switch monotherapies were included in the network. In the original publication, Brignone et al. (2016) included only 5 treatments, excluding citalopram, because remission rates were available only for the subgroup of patients with HAM-D total score Z31 (Lenox- Smith and Jiang, 2008) . This study has been included in the current analysis because citalopram is widely used in many countries, and clinical opinion was that the baseline severity of depression would not be an effectmodifier. Simple adjusted ITCs were made using the Bucher method, which can be applied to both risk differences and odds ratios (Bucher et al., 1997) .
When calculated by ITC, there was a numerically higher probability of remission in favor of vortioxetine versus sertraline (RD, À14.4%), venlafaxine XR (RD, À 7.2%), bupropion SR (RD, À10.7%), and citalopram (RD, À16.8%) (Figure 3) .
Overall, in patients with MDD who have switched from SSRI/SNRI therapy, there is direct evidence that vortioxetine offers clinical benefits over agomelatine and supportive evidence that vortioxetine may offer clinical benefits over other antidepressants in this patient population. In these patients, vortioxetine has demonstrated statistically significant and clinically relevant superior efficacy versus agomelatine. In addition, potentially better efficacy of vortioxetine compared to other commonly used antidepressants (sertraline and citalopram as representatives of SSRIs, venlafaxine as an SNRI, and bupropion as an atypical antidepressant) has also been suggested through indirect comparisons in switching patients.
3. Relative tolerability/safety as switch therapy 3.1. Direct treatment comparison in patients switching due to a lack of efficacy
In the REVIVE study, tolerability was assessed by collecting physician-observed and patient-reported AEs as well as rates of withdrawal due to AEs. The most common treatment-emergent AEs (TEAEs; reported by Z 5% of patients in either treatment group) were nausea, headache, dizziness, and somnolence (Montgomery et al., 2014) . Only nausea had a higher incidence with vortioxetine compared to agomelatine (16.2% vs 9.1%, respectively). Withdrawal due to AEs occurred in 5.9% of the vortioxetine group and 9.5% of the agomelatine group (Montgomery et al., 2014) . Patients receiving vortioxetine had a statistically significantly lower probability of discontinuing treatment because of an AE (RD, 3.6%) compared with agomelatine, based on this direct comparison ( Figure 5 ). # Studies reported remission using MADRS total score; $ Remission could be calculated from scores.
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A post-hoc analysis of REVIVE data indicated that the tolerability profiles (i.e., withdrawal rates and TEAE incidences) of vortioxetine and agomelatine were independent of previous antidepressant treatment, including the division by class (SSRI or SNRI) and by individual therapy (citalopram, escitalopram, paroxetine, sertraline, duloxetine, or venlafaxine) (Papakostas et al., 2014b) . However, the data from the REVIVE study also showed that the incidence of nausea with vortioxetine was lower in patients who had switched therapy compared with treatment-naïve patients included in the overall vortioxetine clinical program.
Because the tolerability results from REVIVE were similar to those observed in the total MDD population (Baldwin et al., 2016) and did not differ by previous treatment (Papakostas et al., 2014a) , the tolerability profile observed in the overall MDD population may be generalizable to patients who switch to vortioxetine from another antidepressant. To further examine the potential for generalizability, a post-hoc analysis of TEAE incidence was performed on the subset of patients with MDD who had received antidepressant pharmacotherapy for their current major depressive episode prior to their inclusion in 1 of 12 short-term studies in the vortioxetine clinical trial program (Alvarez et al., 2012; Baldwin et al., 2012; Boulenger et al., 2014; Henigsberg et al., 2012; Jacobsen et al., 2015b; Jain et al., 2013; Katona et al., 2012; Mahableshwarkar et al., 2015a Mahableshwarkar et al., , 2015b Mahableshwarkar et al., , 2013 McIntyre et al., 2014; Nishimura et al., 2014) . The TEAE profile of previously treated patients was similar to that observed in the overall clinical study population (Table 1) ; however, for many of the most frequent TEAEs, the incidence occurred at a lower rate in the treatment arms of the previously treated subgroup. Rates of study discontinuation also were similar in the switch subgroup and in the overall clinical study population.
Interestingly, the incidence of nausea was lowest in patients who had switched therapy compared with the overall patient population and with treatment-naïve individuals (Table 1) . In treatment-naïve individuals, the incidence rate of nausea was 21.8% for vortioxetine 5 mg/day, 24.6% for 10 mg/day, 34.9% for 15 mg/day, and 32.9% for 20 mg/day, whereas for previously treated patients the incidence of nausea was 16.0%, 18.8%, 25.0%, and 17.7%, respectively, for the same dosages. Additionally, the data from the REVIVE study showed that the incidence of nausea was lower in patients who had switched therapy (16.2%; vortioxetine 10-20 mg/day) than in those who had not received a previous treatment (from the total MDD population).
Indirect treatment comparison
In the ITC, tolerability was assessed as risk differences for withdrawal due to AEs. These risk differences were statistically significantly lower with vortioxetine than with sertraline (RD, 12.1%), venlafaxine XR (RD, 12.3%), and bupropion SR (RD, 18.3%) and were numerically lower than with citalopram (RD, 12.1%) ( Figure 5 ). Using this network-ofevidence approach for the ITC, vortioxetine was found to be numerically more efficacious and better tolerated than a variety of comparator antidepressants commonly prescribed in clinical practice. Although this ITC is limited by the fact that each treatment comparison is based on one study in the network-preventing statistical assessment of the heterogeneity between studies and preventing the ability to account for factors other than the treatment effects in the model-sensitivity analyses (data not shown) supported these conclusions.
Tolerability in patients switching due to intolerable sexual dysfunction
In the study by Jacobsen et al. (2015a) , eligible patients experiencing intolerable TESD while stable on a SSRI regimen for at least 8 weeks were randomized to vortioxetine (10 or 20 mg/day, n = 225) or escitalopram (10 or 20 mg/day, n= 222) in a double-blind, parallel-group, flexible-dose, 8-week study. Patients had depressive symptoms of MDD that were well treated while on an SSRI (citalopram, paroxetine, or sertraline) regimen (MADRS total score at baseline mean 7 standard deviation [SD]: vortioxetine, 7.9 7 6.28; Figure 5 Risk difference for withdrawal due to adverse events, vortioxetine versus comparator. Adapted from Brignone et al. (2016) .
escitalopram, 8.3 7 6.53) with mean baseline CGI-S r 3, consistent with remission .
The primary endpoint was the change from baseline in the Changes in Sexual Functioning Questionnaire Short Form (CSFQ-14), where higher scores indicate better functioning (Keller et al., 2006) . At Week 8, mean increases in CSFQ-14 total score were significantly greater in the vortioxetine group (least squares mean 7 SE: 8.8 7 0.64) than in the escitalopram group (6.6 7 0.64; P= 0.013) . Additionally, improvements in sexual functioning were greater with vortioxetine regardless of age, gender, and baseline depression severity (as measured by CGI-S scores (Guy, 1976)) ( Figure 6 ).
The most common TEAEs (reported by Z5% of patients in either treatment group) were nausea, headache, dizziness, generalized pruritus, irritability, fatigue, and anxiety . Nausea (25.0% vs 5.4%), headache (9.4% vs 7.7%), dizziness (8.0% vs 5.0%), and generalized pruritus (5.8% vs 0%) occurred with a higher incidence with vortioxetine than with escitalopram, respectively. Irritability Table 1 TEAEs with incidence Z5% in any treatment group in the overall MDD population and the subpopulation of MDD patients who had received previous pharmacotherapy.
Percentage of patients (%)
Placebo
Vortioxetine 5 mg Vortioxetine 10 mg Vortioxetine 15 mg Vortioxetine 20 mg Previous, previously treated MDD patient population from 12 short-term trials (Takeda, data on file); Total, total MDD patient population from 11 short-term trials (Baldwin et al., 2016) . a Results for nasopharyngitis not reported in Baldwin et al. (2016) and occurred at incidences o5%. b For the total MDD population, insomnia includes the preferred terms: insomnia, initial insomnia, middle insomnia, hyposomnia, sleep disorder, dyssomnia, poor quality sleep, and terminal insomnia. (7.2% vs 4.9%), fatigue (5.4% vs 4.5%), and anxiety (5.4% vs 2.2%) occurred at a higher incidence with escitalopram than with vortioxetine, respectively. Withdrawal due to an AE occurred in 9.4% of patients in the vortioxetine group and in 6.3% of those in the escitalopram group.
Although the rate of nausea in the vortioxetine group was higher than in the escitalopram group, the rate in the escitalopram group was lower than the 15% seen in phase 3 clinical trials (Forest Pharmaceuticals Inc., 2014) , whereas rates in the vortioxetine group were similar to rates in prior trials. Also consistent with prior trials, most cases of nausea associated with vortioxetine were transient, with a median duration of 7-7.5 days.
Among the patients who were well treated on their previous antidepressant (baseline MADRS total scores 7 SD: vortioxetine, 7.9 7 6.28; escitalopram, 8.3 7 6.53; mean baseline CGI-S r 3 for both groups), efficacy was maintained at Week 8 in both treatment groups (remission rates were 78.7% with vortioxetine and 77.3% with escitalopram; P= 0.902) . Both the vortioxetine and escitalopram groups exhibited further small reductions in mean MADRS total scores during the 8-week treatment period; there were no statistically significant differences or clinically relevant differences between the treatment arms.
The results of this direct comparison suggest that patients who experienced intolerable sexual dysfunction on an SSRI/ SNRI can improve sexual functioning if switched to vortioxetine without losing efficacy of their MDD treatment.
Overall, vortioxetine has been shown to have a favorable safety and tolerability profile consistently across the clinical data package, especially with respect to weight change, sleep, and sexual dysfunction. The vortioxetine tolerability profile was similar to that of agomelatine, an agent considered to have lower rates of adverse events than other antidepressants (Plesnicar, 2014) , and better than that of other commonly used antidepressants (sertraline, venlafaxine XR, bupropion SR, and, with a numerical difference, citalopram).
Discussion
Given the prevalence of MDD and its negative impact on health, economic productivity, and quality of life, the overlapping problems of nonresponse and intolerance to commonly prescribed antidepressant medications is an important public health problem and a critical unmet need in psychopharmacology. For individuals who do not respond adequately to their initial or current treatment, making a decision about the next course of treatment requires multifactorial consideration, including the patients' clinical profile, treatment history, and patient preferences. It is important to offer physicians and patients treatment options that have different mechanisms of action and that have demonstrated efficacy and tolerability in patients needing to switch antidepressant therapy. Patients who do not respond to SSRIs and SNRIs that are typically prescribed in the first 2 "lines" of treatment, may require the use of novel medications with other mechanisms of action.
This review provides a summary of the utility of vortioxetine, a recently introduced antidepressant with a unique profile of receptor effects. Antidepressant effects of SSRIs are attributed to elevations of serotonin (5-HT), mediated via blockade of the 5-HT transporter; SNRIs mediate their antidepressant effects via elevations of 5-HT and (at higher doses) noradrenaline via blockade of the 5-HT transporter and the norepinephrine transporter, respectively. Vortioxetine inhibits the 5-HT transporter and acts as an antagonist at 5-HT 3 , 5-HT 7 , and 5-HT 1D receptors, a partial agonist at 5-HT 1B receptors, and an agonist at 5-HT 1A receptors (Bang-Andersen et al., 2011; Westrich et al., 2012) . These actions lead to modulation of neurotransmission in several systems, including predominantly via serotonin, but possibly also via the norepinephrine, dopamine, histamine, acetylcholine, gamma-aminobutyric acid, and glutamate systems (Sanchez et al., 2015) .
Direct comparisons of vortioxetine with agomelatine demonstrated the efficacy and tolerability of vortioxetine in patients who have failed first-line therapy due to a lack of efficacy and/or tolerability problems. Using a network-ofevidence approach for the ITC, vortioxetine was found to be numerically more efficacious and better tolerated than a variety of comparator antidepressants commonly prescribed in clinical practice. Furthermore, compared with escitalopram, vortioxetine demonstrated greater improvement in sexual functioning, with no loss of efficacy, in patients who were well treated on their previous antidepressant but who switched from an SSRI due to intolerable sexual side effects.
Based on the evidence presented here, vortioxetine is a reasonable treatment choice for switching patients with MDD who experience inadequate response to and/or intolerable side effects during antidepressant treatment with an SSRI or SNRI.
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